appScorecard
Performance
LowHasn't faired well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
HighStrong financials and growth story over the years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
News & Opinions
Ajooni Biotech rights issue to raise Rs 29 cr open on Wednesday
5 months ago•The Hindu Businessline
Ajooni Biotech Standalone September 2022 Net Sales at Rs 10.29 crore, down 44.04% Y-o-Y
6 months ago•Moneycontrol
Ajooni Biotech successfully develops Lumpy Skin Disease Medicine for Cattle
8 months ago•India Infoline
Ajooni Biotech reports standalone net loss of Rs 0.06 crore in the March 2022 quarter
1 year ago•Business Standard
Ajooni Biotech stock ends over 3.5% after sales nearly doubles in Sept 2021
1 year ago•India Infoline
Ajooni Biotech Standalone June 2021 Net Sales At Rs 15.85 Crore, Up 61.18% Y-o-Y
1 year ago•Moneycontrol
Ajooni Biotech Ltd announces impressive results for Q1FY22; Board approves Rights Issue
1 year ago•India Infoline